Teva (TEVA) Continues Early Weakness Following FY12 Outlook
Tweet
Share
E-mailGet Alerts TEVA Hot Sheet
Join SI Premium – FREE
Teva Pharma (Nasdaq: TEVA) continues to slump Wednesday, following guidance for fiscal 2012 which saw earnings and revenues at the low-end of consensus expectations.
Teva sees FY12 sales of $22 billion and non-GAAP EPS of $5.48 to $5.68, versus revs of $21.97 billion and EPS of $5.67 expected on the Street. Although the top-end of earnings beat views, the median calls for something below expectations.
Click here for more color.
Teva sees FY12 sales of $22 billion and non-GAAP EPS of $5.48 to $5.68, versus revs of $21.97 billion and EPS of $5.67 expected on the Street. Although the top-end of earnings beat views, the median calls for something below expectations.
Click here for more color.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UFP Technologies (UFPT) Tops Q2 EPS by 55c
- Vertex (VERX) Tops Q2 EPS by 1c; Offers Guidance
- Black Stone Minerals (BSM) Tops Q2 EPS by 25c
Create E-mail Alert Related Categories
Insiders' BlogRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
